D.E. Shaw & Co
AXDX

D.E. Shaw & Co’s Accelerate Diagnostics AXDX Stock Holding History

D.E. Shaw & Co’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,880
Closed -$619K – 3999
2014
Q3 		$619K Buy
2,880
+1,060
+58% +$206K ﹤0.01% 3181
2014
Q2 		$473K Buy
+1,820
New +$397K ﹤0.01% 3572

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

D.E. Shaw & Co's AXDX Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 22,512 shares — an estimated $324K sold.

D.E. Shaw & Co first reported a position in AXDX in Q2 2014 and held it in 23 quarters. The position peaked at $1.51M in Q2 2020. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 22,512 Accelerate Diagnostics shares in Q2 2022, an estimated $324K.
  • D.E. Shaw & Co first reported a position in Accelerate Diagnostics in Q2 2014 and held it in 23 quarters.
  • D.E. Shaw & Co's Accelerate Diagnostics position peaked at $1.51M in Q2 2020.
  • 74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.